Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.32 |
| ▸ | COPS5 | Q92905 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3142649 | 0.84 | SLC40A1 (0.37) | L3MBTL1NPC1HSP90AA1MAPTKDM4E | |
| SCHEMBL3146703 | 0.77 | NPC1 (0.34) | L3MBTL1NPC1HSP90AA1MAPTKDM4E | |
| SCHEMBL22303825 | 0.77 | MAPT (0.38) | L3MBTL1NPC1HSP90AA1PIP4K2CMAPT | |
| SCHEMBL12338389 | 0.76 | — | — | |
| SCHEMBL20009341 | 0.76 | PIP4K2C (0.40) | L3MBTL1NPC1HSP90AA1PIP4K2CKDM4E | |
| SCHEMBL19249763 | 0.76 | PIP4K2C (0.40) | L3MBTL1NPC1HSP90AA1PIP4K2CMAPT | |
| SCHEMBL826018 | 0.75 | NCF1 (0.50) | L3MBTL1NPC1MAPTKDM4ERAB9A | |
| SCHEMBL11321990 | 0.75 | L3MBTL1 (0.48) | L3MBTL1NPC1HSP90AA1MAPTKDM4E | |
| SCHEMBL10077017 | 0.75 | RPS6KA3 (0.31) | — | |
| SCHEMBL15064745 | 0.75 | HIF1A (0.33) | L3MBTL1NPC1HSP90AA1LMNAIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230295181-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute | 2023-09-21 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2023086428-A2 | NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF | ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-05-19 | — | — | WO | disclosed |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| US-11560389-B2 | Heterocyclic inhibitors of monocarboxylate transporters | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210094969-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2021-04-01 | — | — | US | disclosed |
| US-10851113-B2 | Heterocyclic inhibitors of monocarboxylate transporters | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-12-01 | — | — | US | disclosed |
| US-10752780-B2 | Chromophores for photochromic compositions useful for three dimensional display applications | NITTO DENKO CORPORATION (JP) | 2020-08-25 | — | — | US | disclosed |
| US-7705146-B2 | Hepatitis C inhibitor peptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-27 | — | — | US | disclosed |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION | 2010-04-22 | — | — | US | disclosed |
| US-7678798-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678798-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090197887-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20090197887-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20080108586-A1 | COMBINATION THERAPY FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTION | INCYTE CORPORATION (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108586-A1 | COMBINATION THERAPY FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTION | INCYTE CORPORATION (US) | 2008-05-08 | — | — | US | disclosed |
| US-20070117802-A1 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-24 | — | — | US | disclosed |
| WO-2006000085-A1 | HEPATITIS C INHIBITOR PEPTIDE ANALOGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | L3MBTL1 1131/4885NPC1 826/4885HSP90AA1 2117/4885 |
| US-20070117802-A1 | Met kinase inhibitors | MET, ERBB2, ABL1 | L3MBTL1 1365/4885NPC1 3230/4885HSP90AA1 1311/4885 |
| US-10851113-B2 | Heterocyclic inhibitors of monocarboxylate transporters | SLC16A1, SLC16A3, SLC16A7 | L3MBTL1 4360/4885NPC1 341/4885HSP90AA1 2067/4885 |
| US-20210094969-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | SLC16A1, SLC16A3, SLC16A7 | L3MBTL1 4163/4885NPC1 285/4885HSP90AA1 1996/4885 |
| US-11560389-B2 | Heterocyclic inhibitors of monocarboxylate transporters | SLC16A1, SLC16A3, SLC16A7 | L3MBTL1 4163/4885NPC1 285/4885HSP90AA1 1996/4885 |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | ZC3HAV1, IDO1, ZC3HAV1L | L3MBTL1 2367/4885NPC1 347/4885HSP90AA1 2893/4885 |
| US-10752780-B2 | Chromophores for photochromic compositions useful for three dimensional display applications | CRY1, RB1, BRD3 | L3MBTL1 1594/4885NPC1 4810/4885HSP90AA1 4330/4885 |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | L3MBTL1 3121/4885NPC1 567/4885HSP90AA1 1296/4885 |
| US-20080108586-A1 | COMBINATION THERAPY FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTION | CCR5, HAVCR2, CXCR3 | L3MBTL1 790/4885NPC1 490/4885HSP90AA1 1701/4885 |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | ITGA5, ITGAL, ITGB5 | L3MBTL1 1038/4885NPC1 3783/4885HSP90AA1 778/4885 |
| US-20230295181-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | API5, XIAP, BIRC5 | L3MBTL1 148/4885NPC1 3707/4885HSP90AA1 788/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | L3MBTL1 721/4885NPC1 868/4885HSP90AA1 1704/4885 |
| US-20090197887-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | CCR5, CCR2, CXCR5 | L3MBTL1 4243/4885NPC1 840/4885HSP90AA1 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.